Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Lineage Cell Therapeutics (LCTX) Tax Provisions (2019 - 2023)

Lineage Cell Therapeutics (LCTX) has 4 years of Tax Provisions data on record, last reported at -$1.8 million in Q1 2023.

  • For Q1 2023, Tax Provisions changed N/A year-over-year to -$1.8 million; the TTM value through Dec 2023 reached -$1.8 million, up 83.35%, while the annual FY2025 figure was -$5.3 million, N/A changed from the prior year.
  • Tax Provisions reached -$1.8 million in Q1 2023 per LCTX's latest filing, down from $1.7 million in the prior quarter.
  • Across five years, Tax Provisions topped out at $4.4 million in Q1 2019 and bottomed at -$14.0 million in Q4 2019.
  • Average Tax Provisions over 3 years is -$1.0 million, with a median of $1.0 million recorded in 2019.